Merck halts vorapaxar Phase III trial in ACS patients, amends TRA-2P Phase III trial
This article was originally published in Scrip
Merck has announced major changes to two Phase III clinical studies of vorapaxar, an investigational cardiovascular focused therapeutic candidate that it acquired through the acquisition of Schering-Plough, following a review by a combined data safety and monitoring board. As a result of the safety and efficacy review, the company is discontinuing the TRACER study in patients with acute coronary syndrome (ACS) while the TRA-2P study, which is evaluating the compound in secondary prevention of heart attacks will only continue in a narrower patient population.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.